Cancer in the NCI IBMFS DC cohort
| . | Total no. of cases . | No history of cancer . | All cancers* . | P† . | BMT‡ . | BMF§ . | MDS‖ . | No event¶ . |
|---|---|---|---|---|---|---|---|---|
| Number of cases (%) | 50 | 43 | 7 (14%) | 11 (22%) | 7 (14%) | 5 (9%) | 26 (52%) | |
| Male:female | 37:13 | 33:10 | 4:3 | .4 | 6:5 | 5:2 | 1:4 | 22:4 |
| Median age at outcome, y (range) | NA | NA | 37 (25-44) | 14 (2-47) | 28 (1-53) | 35 (19-61) | NA | |
| Number deceased (%) | 18/50 (36%) | 14/44†† (30%) | 4/6†† (67%) | .2 | 7/11 (64%) | 7/7 (100%) | 2/4 (50%) | 0 |
| Median age at death, y (range) | 29 (1-63) | 26†† (1-63) | 39†† (26-44) | .3 | 24 (2-47) | 28 (1-53) | 46 (30-62) | NA |
| Median survival, y (95% CI), by Kaplan-Meier method** | 42 (36-49) | 42 (35-49) | 46 (35-56) | .6 | 32 (14-42) | 23 (5-40) | NA | NA |
| . | Total no. of cases . | No history of cancer . | All cancers* . | P† . | BMT‡ . | BMF§ . | MDS‖ . | No event¶ . |
|---|---|---|---|---|---|---|---|---|
| Number of cases (%) | 50 | 43 | 7 (14%) | 11 (22%) | 7 (14%) | 5 (9%) | 26 (52%) | |
| Male:female | 37:13 | 33:10 | 4:3 | .4 | 6:5 | 5:2 | 1:4 | 22:4 |
| Median age at outcome, y (range) | NA | NA | 37 (25-44) | 14 (2-47) | 28 (1-53) | 35 (19-61) | NA | |
| Number deceased (%) | 18/50 (36%) | 14/44†† (30%) | 4/6†† (67%) | .2 | 7/11 (64%) | 7/7 (100%) | 2/4 (50%) | 0 |
| Median age at death, y (range) | 29 (1-63) | 26†† (1-63) | 39†† (26-44) | .3 | 24 (2-47) | 28 (1-53) | 46 (30-62) | NA |
| Median survival, y (95% CI), by Kaplan-Meier method** | 42 (36-49) | 42 (35-49) | 46 (35-56) | .6 | 32 (14-42) | 23 (5-40) | NA | NA |
BMF indicates bone marrow failure; and NA, not available.
Data on all cancers include 2 patients with AML (one of whom had MDS that evolved into AML, and then underwent a BMT).
Comparing those with cancer with those without cancer.
Includes 1 patient who had MDS and then AML.
Severe BMF leading to transplantation (scored in BMT) or death.
Includes 1 patient with only MDS; 1 whose MDS evolved to AML; 2 with solid tumors (MDS 13 years after cervical cancer, and tongue SCC 10 years after MDS); and one with a facial basal cell carcinoma 10 years after MDS but within a year after BMT. Thus, 3 MDSs are already counted under All cancers.
No adverse event, that is, no solid tumor before BMT, AML, BMF, or MDS.
The median survival values for patients with and without cancer describe subgroups defined by time-dependent rather than baseline characteristics; therefore, these values should be interpreted as descriptive characteristics of the population rather than predictive probabilities for individual patients.
One patient who had cervical cancer and died later with MDS is included in the numbers and ages of death without cancer.